Darzalex 100 mg Injection – Product Description, Uses and FAQs

Darzalex 100 mg Injection is a prescription oncology medicine containing daratumumab, a monoclonal antibody used in the treatment of multiple myeloma. This blood cancer affects plasma cells, a type of white blood cell found in bone marrow. Daratumumab works by targeting CD38, a protein expressed on the surface of multiple myeloma cells.

Cordium Pharmaceuticals Pvt Ltd provides pharmaceutical product information for healthcare professionals, distributors and international pharmaceutical trade partners. Product availability, sourcing arrangements and applicable regulatory requirements should be confirmed before any commercial transaction.

What Is Darzalex 100 mg Injection Used For?

Darzalex is used in the treatment of eligible adults with multiple myeloma, depending on their treatment history, clinical condition and the applicable country's approved prescribing information. It may be prescribed alone in certain settings or in combination with other cancer medicines, including corticosteroids and other anti-myeloma agents.

Treatment decisions depend on factors such as disease stage, previous therapies, suitability for stem cell transplantation and the patient's overall health. Darzalex should only be used under the supervision of a qualified oncology specialist.

How Does Daratumumab Work?

Daratumumab binds to the CD38 protein on multiple myeloma cells. This interaction helps the immune system identify and destroy targeted cells through several immune-mediated mechanisms. Its targeted action makes it an important option in selected multiple myeloma treatment regimens.

The medicine is administered intravenously by trained healthcare professionals. The exact dose, schedule and accompanying medicines depend on the approved treatment protocol and the patient's individual circumstances.

Important Safety Information

Darzalex may cause infusion-related reactions, respiratory symptoms, nausea, fatigue, fever and changes in blood cell counts. Serious reactions can occur, including severe hypersensitivity reactions and infections.

Patients should inform their healthcare team about existing medical conditions, previous treatments, allergies and all medicines they take. Daratumumab can interfere with certain blood compatibility tests, so the blood bank should be informed before transfusion-related testing.

Patients who experience breathing difficulties, severe allergic symptoms or other serious reactions require immediate medical assessment. The complete prescribing information should be reviewed before treatment.

Frequently Asked Questions About Darzalex 100 mg Injection

1. What is the active ingredient in Darzalex 100 mg Injection?

The active ingredient is daratumumab, a monoclonal antibody targeting CD38. Confirm the strength, concentration and pack details against the product label and relevant market authorization.

2. What condition does Darzalex treat?

Darzalex is used for multiple myeloma in eligible adults. The approved indications and treatment combinations may vary by country and are determined by the relevant regulatory authority.

3. How is Darzalex 100 mg Injection administered?

It is administered intravenously by trained healthcare professionals in an appropriate clinical setting. Patients should not self-administer the intravenous formulation.

4. What are the common side effects of Darzalex?

Possible side effects include infusion-related reactions, fatigue, nausea, fever and low blood cell counts. The nature and severity of side effects vary between patients.

5. Can Darzalex be used with other medicines?

Yes. Depending on the indication, it may be prescribed with other anti-myeloma medicines. Only an oncology specialist should determine the appropriate combination.

6. How can international buyers enquire about Darzalex?

Healthcare distributors and pharmaceutical procurement teams can contact Cordium Pharmaceuticals Pvt Ltd to enquire about product specifications, documentation and potential sourcing arrangements. Supply is subject to product availability, authorization and the import regulations of the destination market.

Contact Cordium Pharmaceuticals Pvt Ltd

For product-related enquiries concerning Darzalex 100 mg Injection, contact Cordium Pharmaceuticals Pvt Ltd for further information about specifications, regulatory documentation and applicable supply requirements. All procurement and distribution must comply with local pharmaceutical laws.

Medical disclaimer: This page is for general informational purposes only and does not replace professional medical advice or the official prescribing information. Darzalex is a prescription medicine and should be used only as directed by a qualified healthcare professional.